Biotech entity
pharma is the sole category represented across all 1 tracked stories. SAB-142 is most often covered alongside DiversitAb, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.3 for that window.
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. SAB-142 is most often covered alongside DiversitAb, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.3 for that window. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. We currently track 1 Biotech story that mention SAB-142, all published on March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SAB-142. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen Downgrade
SABS and SSSS both receive Sell ratings from Wall Street Zen.
SAB-142 Clinical Progress
SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
Strategic Pivot
Company shifts focus from infectious diseases to immunology and chronic conditions.
Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Source: tickerreport.com · tickerreport.com
SAB-142 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
